Evommune (EVMN) Corporate presentation summary

Portfolio overview

• Four programs target chronic inflammatory diseases: EVO301 (IL-18BP), EVO756 (MRGPRX2), EVO570 (VAV1 degrader) and EVO646 (TLR7/8 antagonist).

• EVO301 is advancing in atopic dermatitis (AD) and ulcerative colitis (UC); EVO756 is in a Phase 2b migraine trial; EVO570 and EVO646 are progressing toward Phase 1.

EVO301 in atopic dermatitis

• Long-acting fusion protein built from fully human IL-18 binding protein, designed to neutralize IL-18 signaling; targets multiple inflammatory pathways in AD.

• In Phase 2a (N=70), met the primary endpoint; placebo-adjusted EASI improvement was 34% at Week 8 and 33% at Week 12, with vIGA 0/1 in 23% vs 0% on placebo at Week 12.

• No treatment-related serious or severe AEs or conjunctivitis; PK supported at least Q4-week dosing, and biomarkers and secondary endpoints moved with EASI.

• EASI improvement deepened from 41% to 55% during the eight weeks after the final dose; treatment was given at Weeks 0 and 4.

• Phase 2b dose-ranging trial (N=200) planned for mid-2027, including three active regimens and placebo; primary endpoint is EASI change from baseline at Week 16.

EVO301 in ulcerative colitis

• IL-18 is implicated in epithelial barrier failure; human genetics, patient data and preclinical findings support the target, including evidence that IL-18 can impede barrier repair.

• Phase 2a proof-of-concept trial planned in moderate-to-severe UC (N~84), with IV dosing at baseline, Weeks 2 and 4, and efficacy assessments through Week 12.

• UC Phase 2a initiation planned for 1H 2027; internal estimates place the AD opportunity at ~$60B and IL-18-driven diseases including AD and IBD at ~$100B.